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Abstract
The membrane proximal region (MPR, residues 649–683) and transmembrane domain
(TMD, residues 684–705) of the gp41 subunit of HIV-1’s envelope protein are highly con-
served and are important in viral mucosal transmission, virus attachment and membrane
fusion with target cells. Several structures of the trimeric membrane proximal external
region (residues 662–683) of MPR have been reported at the atomic level; however, the
atomic structure of the TMD still remains unknown. To elucidate the structure of both MPR
and TMD, we expressed the region spanning both domains, MPR-TM (residues 649–705),
in Escherichia coli as a fusion protein with maltose binding protein (MBP). MPR-TM was ini-
tially fused to the C-terminus of MBP via a 42 aa-long linker containing a TEV protease rec-
ognition site (MBP-linker-MPR-TM). Biophysical characterization indicated that the purified
MBP-linker-MPR-TM protein was a monodisperse and stable candidate for crystallization.
However, crystals of the MBP-linker-MPR-TM protein could not be obtained in extensive
crystallization screens. It is possible that the 42 residue-long linker between MBP and MPR-
TM was interfering with crystal formation. To test this hypothesis, the 42 residue-long linker
was replaced with three alanine residues. The fusion protein, MBP-AAA-MPR-TM, was sim-
ilarly purified and characterized. Significantly, both the MBP-linker-MPR-TM and MBP-
AAA-MPR-TM proteins strongly interacted with broadly neutralizing monoclonal antibodies
2F5 and 4E10. With epitopes accessible to the broadly neutralizing antibodies, these
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MBP/MPR-TM recombinant proteins may be in immunologically relevant conformations
that mimic a pre-hairpin intermediate of gp41.
Introduction
The transmembrane (TM) domain of HIV-1 gp41 is one of the most highly conserved regions
of the envelope glycoprotein (Env) of HIV-1 [1, 2]. This region is involved in many essential
biological functions (recently reviewed by Steckbeck and co-workers [3]). The primary role of
the gp41 TM domain is to anchor Env in both the viral and cellular membranes [4]. It has been
recently reported that the TM domain also induces lipid mixing and associates with the fusion
peptide of HIV-1 gp41 during the viral fusion process [5]. The gp41 TM peptide was able to
inhibit virus-cell fusion because it associates strongly with the fusion peptide and thus may
interfere with insertion of the fusion peptide into the target cell membrane, which makes the
gp41 TM peptide a new and fascinating HIV-1 entry inhibitor [5]. Additionally, the gp41 TM
domain shares a motif with the α subunit of the T-cell receptor TM domain [2]. The gp41 TM
peptide co-localizes with CD3 in the T-cell receptor complex and inhibits T cell proliferation
in vitro, and this interaction was suggested to be yet another strategy whereby HIV-1 evades
immune responses [6].
Mao et al. reported a 6Å resolution cryo-electron microscopy structure of the membrane-
bound HIV-1 envelope glycoprotein trimer in its uncleaved state, which included the TM
domain of gp41 [7]. This report comprises the only structural information of the TM domain
of gp41. The atomic structure of the gp41 TM domain remains unknown perhaps due to its
high hydrophobicity making its expression, purification and crystallization difficult. The tradi-
tional model of the gp41 TM domain is a single membrane-spanning α-helix (residues 684–
705) followed by an intracytoplasmic C-terminal tail [2]. An alternative model was proposed
by Hollier and Dimmock [8] to explain the observation that an epitope in the C-terminal tail of
HIV-1 gp41, the so-called Kennedy epitope [9], is extracellulary exposed under some condi-
tions. To account for the drastic change in the membrane topology necessary for the exposure
of the Kennedy epitope, Hollier and Dimmock suggested that under certain conditions the TM
region assumes a different secondary structure consisting of three membrane-spanning β-
sheets [8].
HIV-1 gp41 is essential in transcytosis, a process leading to mucosal transmission of the
virus [10–12]. Transcytosis is initiated when gp41 binds to the epithelial glycosphingolipid
galactosyl ceramide (GalCer), the epithelial cell receptor for HIV [13]. The minimal region
required for gp41 to bind GalCer is the membrane proximal region (MPR, residues 650–685)
[14]. MPR is another highly conserved segment of HIV-1 [2, 15] and contains the membrane
proximal external region (MPER, residues 662–683) and part of the C-terminal heptad repeat
region (CHR, residues 650–661). Furthermore, MPR is the target of secretory IgAs, which
block HIV-1 transcytosis by neutralizing gp41 binding to GalCer [16, 17]. Significantly, epi-
topes in the MPER are recognized by three broadly neutralizing antibodies, 2F5 [18], 4E10 [19]
and 10E8 [20].
HIV-1 gp41 mediates the membrane fusion between target cell and virus through its own
conformational changes: from a native trimer prior to the interaction between gp120 and CD4,
through a pre-hairpin intermediate, and then as a post-fusion trimer of hairpins (or a six-helix
bundle) [21]. Structures of trimeric MPER have been solved in the pre-fusion [22] and post-
fusion (six-helix bundle) conformations [23]. However, neither conformation could be
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recognized by the broadly neutralizing antibodies 2F5 or 4E10 [22, 23]. Another structure of
trimeric MPER has been solved in the post-fusion state (a six-helix bundle) containing a short-
ened NHR (HR1) region, which leaves MPER accessible to the 2F5 antibody [24]. Recently,
Reardon et al. reported an NMR structure of the trimeric MPER in a putative pre-fusion inter-
mediate state (a three-helix bundle) [25]. In their structure, the N termini of the MPER helices
are closely associated with each other while the C termini gradually separate, which leaves
space for antibody binding. However, in their construct, MPER was fused to the C terminus of
a 27-residue trimerization domain from bacteriophage T4 fibritin (the foldon domain).
Although Reardon et al. reported that MPER was linked to the foldon motif through the flexi-
ble linker GSSG, which is intended to minimize the effect of the structured trimerization motif
on the conformation and dynamics of MPER, it is still not experimentally confirmed that
MPER forms a trimer in the pre-fusion intermediate form without the effect of the trimeriza-
tion motif. Moreover, the tight association of the MPER trimer at the N terminus could be due
to its proximity to the tight foldon motif while the C terminus of the MPER trimer separated
from each other because the C terminus of the MPER trimer has less effect from the trimeriza-
tion motif. To better understand HIV-1 gp41 and instruct design of vaccines and therapeutics
against HIV-1, elucidating the structure of the gp41 MPR and TM domains is required.
Mistic, a Bacillus subtilis integral membrane protein [26], was previously used as a fusion
partner in our laboratory to overexpress MPR-TM of HIV-1 gp41, upon which Mistic was
removed for crystallization [27]. However, no crystals were obtained even after extensive crys-
tallization screens. This result may be due to the highly hydrophobic property of MPR-TM
and/or lack of crystal contacts between MPR-TMmolecules. In the work reported here, a novel
construct was designed to overexpress MPR-TM as a maltose binding protein (MBP) fusion.
MBP is a commonly used fusion partner, capable of improving the solubility and expression
level of the target protein [28–32]. MBP may function as a chaperone to assist the correct fold-
ing of the target protein in active form [28]. Furthermore, MBP may provide a large hydro-
philic interaction surface for formation of crystal lattice contacts thereby facilitating crystal
formation [33]. Structures of dozens of MBP recombinant proteins have been solved at atomic
resolution by X-ray structure analysis in the past decades (reviewed in Refs. [33, 34]), which
indicates that MBP could be used as a fusion partner for structural studies.
In the present study, we report the expression, purification and biophysical characterization
of MPR-TM (residues 649 to 705) as a C-terminal fusion to the 8xHis-tagged MBP for struc-
tural determination by X-ray crystallography. Surface plasmon resonance (SPR) was used to
test if the epitope on the purified protein was exposed and could be recognized by the broadly
neutralizing mAbs 2F5 and 4E10. Crystals of the MBP/MPR-TM recombinant protein could
not be obtained when MPR-TM was fused to the C-terminus of MBP via a 42-residue linker.
The linker was changed to three alanine residues (MBP-AAA-MPR-TM) which may be more
suitable for crystallization.
Materials and Methods
Cloning and expression of MBP-linker-MPR-TM and
MBP-AAA-MPR-TM
The coding region of gp41 MPR-TM flanked by a tobacco etch virus (TEV) cleavage site was
subcloned from pMistic-MPR-TM [27] into the pCR8/GW/Topo vector (Invitrogen, Carlsbad,
CA), sequence-verified and shuttled into the pVP16 destination vector [35] by Gateway recom-
bination cloning (Invitrogen, Carlsbad, CA). An aliquot of the LR reaction was used to trans-
form One Shot TOP10 chemically competent E. coli cells following the protocol provided by
the manufacturer (Invitrogen, Carlsbad, CA). Recombinant clones were selected on LB agar
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plates supplemented with 100 μg/mL of ampicillin. Plasmid DNA was isolated from several
colonies using QIAGEN Plasmid Mini Kit (QIAGEN, Valencia, CA) and digested with EcoRI
and KpnI (Promega, Madison, WI) to confirm the presence of the insert in pVP16. Vectors
and their sequences have been deposited and are available at the PSI:Biology-Materials Reposi-
tory at DNASU (DNASU Plasmid ID: HiCD00674886) (http://dnasu.org) [36]. The verified
recombinant expression vector of MBP-linker-MPR-TM was further transformed into NEB
Express competent cells (New England Biolabs, Ipswich, MA), an enhanced BL21 derivative
that allows inducible recombinant protein expression from T5 and other non-T7 promoters.
Recombinant clones of MBP-linker-MPR-TM were selected on LB plates supplemented with
100 μg/mL of ampicillin.
To construct the gene encoding MBP-AAA-MPR-TM, a 153 bp BglII and SalI restriction frag-
ment that encompasses a region of the MBP-linker-MPR-TM coding sequence that encodes the
long linker and a TEV protease recognition site (spanning EALKDAQ. . .ENLYFQG, S1 Fig) was
replaced with a DNA sequence that encodes the protein sequence AALAAAQTNAAA. This
cloning was accomplished with the following PCR reactions using Takara PrimeSTARMax
DNA Polymerase (Clontech, Mountain View, CA; see S1 Table for the primer sequences). PCR1
used primers MBP-MPR-fuseF1 and insert1-PCR1R, and template MBP-linker-MPR-TM; PCR2
used primers MBP-MPR-fuseF1 and insert1-PCR2R, and template PCR1; PCR3 used primers
insert2-PCR1F and MBP-MPR-fuseR1, and template MBP-linker-MPR-TM; PCR4 used primers
MBP-MPR-fuseF2 andMBP-MPR-fuseR1, and template PCR2. The products of PCR3 and
PCR4 were simultaneously inserted into BglII- and SalI-digested MBP-linker-MPR-TM using
the ligation-independent InFusion HDCloning Plus system (Clontech) [37]. DNA sequence con-
firmation was performed at the School of Life Sciences DNA Laboratory at Arizona State Univer-
sity. Vectors and their sequences have been deposited and are available from the PSI:Biology-
Materials Repository at DNASU (DNASU Plasmid ID: HiCD00674843, http://dnasu.org) [36].
The verified recombinant expression vector of MBP-AAA-MPR-TMwas further transformed
into BL21(DE3) competent cells (Invitrogen). Recombinant clones of MBP-AAA-MPR-TM
were selected on LB plates supplemented with 100 μg/mL of ampicillin.
Bacterial overexpression of both fusion proteins was done as follows. A single bacterial colony
was used to inoculate a 100 mL pre-culture in LB containing 100 μg/mL of ampicillin in a
shaker-incubator (37°C, 200 rpm) overnight. This culture was used to inoculate 3 L of LB broth
containing 100 μg/mL of ampicillin at a dilution ratio of 1:30. Cells were grown at 37°C until the
culture density reached OD600 between 0.6 and 0.8. Protein expression was induced by adding
isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 500 μM and continued
incubation for an additional 4 h. Cells were harvested by centrifugation (5000 ×g, 10 min, 4°C)
and cell pellets (12–14 g of wet cells per 3 L culture) were then stored at -80°C until further use.
Preparation of the crude membrane fractions of MBP-linker-MPR-TM
and MBP-AAA-MPR-TM
Preparation procedures of the crude membrane fractions of MBP-linker-MPR-TM and
MBP-AAA-MPR-TM were the same. Cell pellets stored at -80°C were thawed and re-sus-
pended in ice-cold phosphate buffered saline (PBS; 137 mMNaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4, pH 7.4) with 1× EDTA-free protease inhibitor (Sigma S8830).
100 mL of PBS buffer containing protease inhibitor was used to re-suspend 15 g of wet cell pel-
let. The suspension was disrupted in an ultrasonic homogenizer (Model 300 V/T, Biologics) at
150 W and 10 kHz for 1 min on and 1 min off while kept on ice. This step was repeated three
times in total. The cell lysate was centrifuged at 20,000 ×g for 20 min at 4°C. The supernatant
Crystallizability of HIV gp41-MBP Fusion Proteins
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was discarded and the pellet, containing the membrane fraction, peptidoglycan cell wall and
other aqueous-insoluble material, was stored at -80°C overnight.
Detergent solubilization of MBP-linker-MPR-TM and
MBP-AAA-MPR-TM
The frozen crude membrane fraction of MBP-linker-MPR-TMwas thawed and resuspended in
ice-cold PBS buffer with protease inhibitor. 100 mL of PBS buffer containing protease inhibitor
was used to re-suspend per 15 g of crude membrane fraction. Detergent screens were conducted
by adding the following detergents to 1% (w/v) final concentration: lauryldimethylamine-oxide
(LDAO), n-decyl-β-D-maltoside (β-DM), and n-dodecyl-β-D-maltoside (β-DDM). These sus-
pensions were incubated at 4°C for 2 h. Screening for the optimal length of time required for effi-
cient detergent extractions was done essentially as described above except that the incubation
time was varied among 0.5 h, 1 h, 2 h and 3 h. Following their incubation, the suspensions were
centrifuged at 20,000 ×g for 20 min and the supernatant, which contained detergent-soluble pro-
teins, was then used for further analyses. Large scale extractions were performed at using 1%
βDDM at 4°C for 1 h.
Purification of MBP-linker-MPR-TM and MBP-AAA-MPR-TM
Purification procedures of MBP-linker-MPR-TM and MBP-AAA-MPR-TM were the same.
The detergent-solubilized proteins were purified by metal-affinity FPLC using a nickel-nitrilo-
triacetic acid (Ni-NTA) Superflow column (QIAGEN). The Ni-NTA Superflow resin was man-
ually packed into the Tricon Empty 10/100 column (GE Healthcare, bed volume 8 mL). The
column was equilibrated with buffer A (500 mMNaCl, 20 mM bicine, pH 8.0, and 0.05% β-
DDM). The detergent soluble fraction was injected onto the Ni-NTA Superflow column by a
10 mL superloop (GE Healthcare) and washed with buffer A until the A280 was stable below
10 mAu. To remove non-specifically-bound proteins, the column was then washed with 2%
buffer B (buffer A with 500 mM imidazole; final concentration of imidazole was 10 mM) until
the A280 was stable below 20 mAu. Specifically-bound proteins were eluted from the column by
application of a linear gradient of buffer B from 2% to 50% in 25 min at 1 mL/min. The eluted
proteins were concentrated to 10–20 mg/mL using concentrators (100-kDa cutoff polyether-
sulfone membrane, Sartorius). Concentrated proteins were then subjected to size exclusion
chromatography (SEC) using a Superdex-200 HR 10/300 gel filtration column (GE Healthcare)
in SEC buffer (20 mMNaCl, 20 mM Tris-HCl, pH 7.5, 0.015% β-DDM). The Superdex-200
column was calibrated using the standards aprotinin (6.5 kDa), RNase A (13.7 kDa), carbonic
anhydrase (29 kDa), ovalbumin (43 kDa), conalbumin (75 kDa), aldolase (158 kDa) and ferri-
tin (440 kDa). Protein purity was analyzed by SDS-PAGE.
The protein concentration of MBP-linker-MPR-TM and MBP-AAA-MPR-TM were deter-
mined spectrophotometrically at 280 nm using molar extinction coefficients of 98,290 cm-1M-1
and 94,450 cm-1M-1, respectively.
Cleaving MBP-linker-MPR-TM with TEV protease
After SEC purification, samples’ buffer conditions were adjusted to allow optimal TEV cleavage
(final concentrations of 50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA and 1 mMDTT). The recom-
binant protein MBP-linker-MPR-TM was digested with TEV protease (TEV: Substrate = 1 μg:
400 μg) [38] for 2 h at room temperature. Samples incubated in the same buffer without the
TEV protease served as negative controls. The TEV protease cleavage products were subjected
to a second Ni affinity purification step to purify the cleaved MPR-TM (collected in the flow-
through, while the His-tagged MBP remains adsorbed to the column).
Crystallizability of HIV gp41-MBP Fusion Proteins
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SDS-PAGE and associated analyses
Proteins were resolved by SDS-PAGE and gels were either silver stained or subjected to immu-
noblotting as previously described [27]. Briefly, SDS-PAGE was performed with Tricine-SDS
gels with 4% stacking and 8% separating gels. The primary antibody (1:2000 dilution) used in
immunoblots was BSA-free monoclonal mouse Penta His antibody (QIAGEN), and the sec-
ondary antibody (1:2000 dilution) was goat anti-mouse polyclonal IgG-HRP (Invitrogen).
Purity of recombinant protein preparations were estimated by densitometric analysis of
Coomassie-stained SDS-PAGE with ImageJ [39]. The gel was overloaded with 50 μg of MBP-
linker-MPR-TM and MBP-AAA-MPR-TM proteins, which allowed more sensitive detection
of contaminating proteins [40]. ImageJ was used to quantify the integrated density of each
band and protein purity was calculated based on the density percentage.
Clear Native PAGE analysis
NativePAGETM 4–16% Bis-Tris gel (Invitrogen) was used for clear native electrophoresis.
Protein samples in the presence of 0.02% β-DDM were mixed with 2X native sample buffer
(100 mM sodium chloride, 100 mM imidazole-HCl, 4 mM 6-aminohexanoic acid, 10% glycerol
and 2 mM EDTA, pH 7.0) [41]. The cathode buffer contains 50 mM Tricine, 7.5 mM imidaz-
ole, pH 7.0 and the anode buffer contains 25 mM imidazole, pH 7.0 [42].
The relative mobilities (Rf) of protein standards were plotted against the known molecular
mass (MW) values of the standards. Nonlinear regression was used to obtain the following for-
mula: MW = 2054e-3.6Rf-65 (R2 = 0.99); the formula in turn was used to interpolate the appar-
ent molecular masses associated with the proteins bands.
The relative mobilities (Rf) of protein standards were plotted against the known molecular
mass (MW) values of the standards. Nonlinear regression was used to obtain the following for-
mula: MW = 2054e-3.6Rf-65 (R2 = 0.99); the formula in turn was used to interpolate the appar-
ent molecular masses associated with the proteins bands.
Biophysical analyses
Dynamic light scattering (DLS) measurements were carried out using DynaPro NanoStar
M3300 fromWyatt as previously described [27]. The sample’s polydispersity distribution is the
standard deviation of the histogram that refers to the width of the peak [43]. The percent poly-
dispersity (% polydispersity) is the polydispersity divided by the estimated hydrodynamic
radius multiplied by 100. MALDI-TOF-MS was performed as previously described [27].
Circular dichroism (CD) spectra of purified proteins were measured by a JASCO J-710 CD
spectropolarimeter [27]. Far UV CD spectra (185–260 nm) were recorded at 20°C in a 0.01 cm
cuvette using the following parameters: scan speed, 50 nm/min; scanning increment, 0.5 nm;
spectral bandwidth, 1.0 nm; response, 4 s. Reported spectra represent the average of 5 scans
corrected for background solvent effects by subtraction of the appropriate blank and expressed
as molar ellipticity. When comparing samples of MBP, MBP-Linker-MPR-TM and MPR-TM,
proteins were diluted into 20 mM Tris-HCl, pH 7.5, 150 mMNaCl, and 0.02% β-DDM to an
equimolar final concentration of 13 μM.
In order to study the effect of ionic strength on the secondary structure, the protein sample
was concentrated to 5 mg/mL as described above and then diluted 20-fold into buffers contain-
ing 20 mM Tris-HCl, pH 7.5, 0.02% β-DDM and 0, 20, 50, 100, 150, 200, 250 or 300 mMNaCl.
In order to identify the effect of pH on the secondary structure, the 5 mg/mL protein sample
was diluted 20-fold into buffers containing 150 mMNaCl and 0.02% β-DDM at pH 6.5, 7.0,
7.5, 8.0 or 8.5. Prior to CD measurements, protein samples were incubated in the appropriate
buffer overnight.
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Analysis of the secondary structure content based on CD data was carried out using the
CDPro software package [44]. Three methods CDSSTR [44–46], CONTIN/LL [47, 48], and
SELCON3 [44, 49] were run using a protein reference set of 43 soluble proteins and 13 mem-
brane proteins (SMP56) [44]. The average and standard deviation of the results from these
three methods were calculated.
For thermal denaturation measurements monitored by CD spectroscopy, the CD signal at
220 nm was recorded from 15 to 90°C with a temperature change of slope at a rate of 2°C/min.
The apparent midpoint temperature of the transition was calculated from the first derivative of
the thermal melting curve.
Surface plasmon resonance
All experiments were performed in quadruplicate on a KX5 Surface Plasmon Resonance Imag-
ing (SPRi) System (Plexera) as previously described [27]. 10 μg/ml mAbs 2F5 (catalog number
1475) and 10 μg/ml 4E10 (catalog number 10091) were immobilized onto the surface of the
gold chip (Plexera). The authors thank the NIH AIDS Research and Reference Reagent Pro-
gram (Divisions of AIDS, NIAID, NIH) for donation of the mAbs 2F5 and 4E10. MBP (frac-
tions A2 from SEC purification, Fig 1C) at 240 nM was used as a negative control. The purified
MBP-linker-MPR-TM protein and MBP-AAA-MPR-TM protein were measured at 187 nM
and 205 nM, respectively. Identical injections over blank surfaces were subtracted from the
data for kinetic analyses.
Results and Discussion
Cloning and expression of MBP-linker-MPR-TM
In order to improve the expression level and solubility of the membrane proximal region and
transmembrane (MPR-TM) domains of HIV-1 gp41, MPR-TM was fused to the C terminus of
the maltose binding protein (MBP) by a 42 aa-long linker containing a tobacco etch virus
(TEV) protease cleavage site (S1 Fig). An 8xHis-tag was cloned onto the N-terminus of MBP
for purification purpose (S1 Fig). The MBP-linker-MPR-TM recombinant protein was
expressed in NEB Express E. coli, a BL21 derivative-strain.
Detergent solubilization of MBP-linker-MPR-TM
Anti-His immunoblot analyses of purification fractions indicated that most of the MBP-linker-
MPR-TM fusion protein was in the water-insoluble fraction (S2A Fig). To establish the optimal
solubilization conditions, we tested 1% LDAO, 1% β-DM and 1% β-DDM. The three deter-
gents were able to extract the majority of the MBP-linker-MPR-TM protein from the pellet,
and their extraction efficiencies were similar as judged by immunoblot analysis (S2B Fig). β-
DDM was chosen for future purification because it has been widely and successfully used in
crystallization of membrane proteins [50]. Analysis of the time needed for efficient detergent
extraction showed that a 1 h incubation was sufficient to extract the majority of the MBP-
linker-MPR-TM protein (S2C Fig).
Purification of MBP-linker-MPR-TM
Purification of βDDM-solubilized MBP-linker-MPR-TM protein was accomplished by FPLC-
connected Ni-affinity chromatography followed by size exclusion chromatography (SEC) in
the presence of βDDM. A single elution peak was obtained from Ni-affinity column (Fig 1A).
SDS-PAGE analysis of the flowthrough and elution peaks indicated two protein bands, one
above the 50 kDa marker and one below (Fig 1B). These two proteins were successfully
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separated into peak A1 and peak A2 by SEC (Fig 1C) as determined by SDS-PAGE analysis
(Fig 1D). Both bands were recognized by anti-His antibodies (Fig 1D), indicative of an intact
8xHis tag. MALDI-TOF MS analysis demonstrated that SEC peak A1 contains a protein of
53,319 Da (Fig 2A), possibly representing the MBP-linker-MPR-TM fusion protein (theoretical
molecular weight: 53,389 Da). The signal atm/z 26,641 is likely to correspond to MBP-linker-
MPR-TM charged with two protons. Peak A2 from the SEC purification contained proteins
with masses ranging from 43,818 Da to 45,814 Da (Fig 2B). The theoretical molecular weight
of the MBP itself is 41,694 Da (Fig 2C). MBP including the linker would have a molecular
weight of 46,376 Da (Fig 2C). Therefore, proteins eluted in SEC peak A2 represent a number of
C-terminally truncated versions of the recombinant fusion protein, which includes intact MBP
(Fig 1C). The protein eluted in SEC peak A1 (Fig 1C) was used for further analyses. The purity
of MBP-linker-MPR-TM, estimated by the densitometric analysis of an overloaded gel (S3A
Fig), was>96%. The yield of MBP-linker-MPR-TM was approximately 60 mg per liter of
culture.
MBP-linker-MPR-TM forms oligomers and is monodisperse
SDS-PAGE and MALDI-TOF MS analysis can only be used to determine the molecular weight
of the monomeric MBP-linker-MPR-TM because the proteins were denatured and lost their
structural integrity and oligomeric state in these two analysis methods. The molecular weight
Fig 1. Purification of MBP-linker-MPR-TM. (A) Ni-affinity chromatogram of the βDDM extraction. Blue
curve: UV absorbance at 280 nm; green curve: percentage of buffer B. (B) SDS-PAGE analysis of the
flowthrough peaks and elution peak of the Ni-affinity chromatography. (C) SEC of the elution from Ni-affinity
chromatography. Blue curve: UV absorbance at 280 nm. Peak A1 eluted at 11.1 mL and peak A2 eluted at
16.3 mL. (D) Silver stained SDS-PAGE (left) and anti-His Western blot (right) analysis of the peak A1 and A2
from SEC. L: molecular weight ladder.
doi:10.1371/journal.pone.0136507.g001
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of MBP-linker-MPR-TM in its detergent solubilized state was analyzed by analytical SEC,
dynamic light scattering (DLS), and clear native PAGE.
Fig 2. MALDI-TOF MS analysis of elutions from SEC. (A) MALDI-TOF MS analysis of the peak A1 from SEC (Fig 1C). (B) MALDI-TOF MS analysis of the
peak A2 from SEC (Fig 1C). (C) Schematic representation of the MBP-linker-MPR-TM protein and predicted molecular weights of protein fragments.
Residues 414–420 in green: TEV protease recognition site.
doi:10.1371/journal.pone.0136507.g002
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The elution fraction from the Ni-affinity chromatography purification was analyzed by ana-
lytical SEC (Fig 1C). Based on the standard curve calibration, the A2 SEC peak (Fig 1C, center-
ing at 16.3 mL) corresponded to proteins with MW of<50 kDa, which indicated that the
various partially truncated fusion proteins containing intact MBP remained monomeric as has
been previously reported for MBP [51]. The A1 SEC peak (Fig 1C, centering at 11.1 mL) corre-
sponded to proteins with a MW of ~470 kDa based on our calibration. Considering that the
proteins are embedded in large β-DDMmicelles, the exact oligomeric state is difficult to assess,
but is likely at least a hexamer. Previous studies demonstrated that MBP by itself is a monomer
[51] but recombinant MBP fusion proteins may form oligomers depending on the nature of
the fusion partner [29, 52, 53]. Our SEC results therefore provide an indication that it is the
MPR-TM that is responsible for the oligomerization of MBP-linker-MPR-TM.
The size of a protein-detergent micelle estimated by SEC provides just a rough estimation
of its size [54]. DLS was utilized in addition to estimate the molecular weight of MBP-linker-
MPR-TM in the form of the protein-detergent complex (Fig 3). The hydrodynamic radius
of the detergent-protein complex was 7.7 ± 0.5 nm, which corresponds to a molecular mass
of about 400 kDa (S2 Table). This result is slightly different from the estimation by SEC
(~470 kDa). Although both SEC and DLS can be used to roughly estimate the size of molecules
in solution, the estimation by neither approach is accurate for membrane proteins because
both DLS and SEC assume a spherical particle that is very likely not the case for our fusion pro-
tein. The most important function of DLS in our study is to measure the sample’s polydisper-
sity distribution. The level of homogeneity is considered high when the percent polydispersity
is less than 15% [55]. As shown in Fig 3 and S2 Table, the percent polydispersity of the peak is
13.4%, which indicated that the purified MBP-linker-MPR-TM is a monodisperse candidate
for crystallization. It is concluded from the SEC and DLS analyses that MBP-linker-MPR-TM
formed an oligomer in the presence of β-DDM. The presence of the detergent is vital for the
stability of the protein in solution. This is evident when the fusion protein is subjected non-
denaturing (native) PAGE analysis in the absence of detergents (S4 Fig). Under these condi-
tions, the fusion protein, but not the MBP carrier protein by itself, is shown to maintain its olig-
omeric structure (S4 Fig, S4 Table). However, being partially stripped of its detergent layer, the
oligomers tend to stack with regularity to form discrete complexes that resolve as a ladder (S4
Fig, S4 Table).
Fig 3. DLSmeasurement of 2 mg/ml MBP-linker-MPR-TM indicatedmonodispersity.
doi:10.1371/journal.pone.0136507.g003
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Secondary structure estimation of MBP-linker-MPR-TM and MPR-TM by
CD
It is essential to test if the purified MBP-linker-MPR-TM is folded well before carrying out
crystallization screens. The results of CD measurement (Fig 4A, black trace) displayed one pos-
itive band at 193 nm and two negative bands at 208 and 222 nm, which is characteristic of a
protein with a large fraction of α-helices [56]. Analysis of the secondary structure content of
MBP-linker-MPR-TM by CDPro indicated the presence of 39.3 ± 2.3% α-helix, 13.5 ± 1.8% β-
sheet and 47.3 ± 1.5% random coil. Comparison of the CD spectra of MBP (fraction A2 in Fig
1C) and MBP-linker-MPR-TM (fraction A1 in Fig 1C) demonstrated that the two minima of
MBP-linker-MPR-TM were lower than that of MBP (Fig 4A, blue trace). Analysis of the sec-
ondary structure content of MBP by CDPro showed that MBP contained 33.0 ± 2.6% α-helix,
15.2 ± 2.4% β-sheet and 51.8 ± 1.2% random coil. The higher α-helix content in MBP-linker-
MPR-TMmight be due to the presence of MPR-TM.
To test the hypothesis that the HIV-1 MPR-TM domains contribute to the CD spectrum of
the fusion protein, we separately measured the CD spectrum of MPR-TM that was cleaved
from the fusion recombinant protein by TEV protease. The cleavage products contained
cleaved MBP, MPR-TM and TEV protease (lane 2 in S5 Fig). Since the concentration of TEV
protease used in the reaction was very low, the band of TEV protease could not be detected. A
negative control without TEV protease was set up and analyzed by SDS-PAGE. In the negative
control, MBP-linker-MPR-TM was not cleaved (lane 3 in S5 Fig). Subsequently, the TEV pro-
tease cleavage products were separated using a second Ni-affinity purification step. Cleaved
MPR-TM was collected in the flow-though (lane 4 in S5 Fig) while the His-tagged MBP and
TEV protease were retained on the column and subsequently eluted by imidazole (lane 5 in S5
Fig).
The CD spectrum of cleaved MPR-TM displayed one positive peak at 193 nm and two nega-
tive peaks at 208 and 222 nm (Fig 4A, red trace). Analysis of the secondary structure content of
cleaved MPR-TM by CDPro indicated the presence of 76.3 ± 0.8% α-helix, 2.3 ± 1.0% β-sheet
and 21.4 ± 1.7% random coil. The molar ellipticities of the MBP and MPR-TM (Fig 4A blue
and red traces, respectively) are additive and the resultant curve is essentially identical with the
measured curve of the fusion protein (Fig 4A green and black traces, respectively), suggesting
the secondary structure of MPR-TM is not measurably affected within the context of the fusion
protein. Moreover, our results fit published observations made with pre- and post-fusion Env
using crystallography and cryo-electron microscopy [7, 22–24].
Thermal stability of MBP-linker-MPR-TM
In order to estimate the thermal stability of the MBP-linker-MPR-TM protein and to guide
decisions of the optimal temperature at which crystallization screens should be performed, CD
spectroscopy was used. The CD spectra showed that the apparent midpoint “denaturation”
temperature (TM) of the sample was 50°C (Fig 4B), which indicated good thermal stability.
According to the melting curve obtained, the MBP-linker-MPR-TM protein would not dena-
ture below 45°C (Fig 4B). Therefore, crystallization screens of MBP-linker-MPR-TM could be
performed at room temperature or lower temperatures.
Effect of ionic strength and pH on the secondary structure of MBP-linker-
MPR-TM
Ionic strength and pH are two important parameters which could be adjusted in crystallization
screens to promote crystal formation. We used CD measurements to investigate the effect of
Crystallizability of HIV gp41-MBP Fusion Proteins
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Fig 4. CD analysis of MBP-linker-MPR-TM, MPR-TM andMBP. (A) CD spectra of MBP-linker-MPR-TM,
MPR-TM and MBP. Buffer: 100 mMNaF, 20 mMNaH2PO4, pH 7.5, and 0.02% βDDM. Protein concentration
was 0.26 mg/mL. (B) Thermal denaturation curve of MBP-linker-MPR-TMmeasured at 220 nm and at a rate
of temperature change of 2°C/min. The apparent midpoint “denaturation” temperature of the protein was
50°C. Protein concentration was 0.5 mg/mL. (C) Effect of ionic strength on the secondary structure of MBP-
linker-MPR-TM. CDmeasurements were performed in 20 mM Tris, pH 7.5, 0.02% βDDM containing 0 to
Crystallizability of HIV gp41-MBP Fusion Proteins
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ionic strength and pH on the secondary structure of the MBP-linker-MPR-TM protein to
determine the range of these two parameters in which the protein would be correctly folded
under crystallization conditions. The purified MBP-linker-MPR-TM protein was concentrated
to 5 mg/mL and diluted into buffers containing 0 to 300 mMNaCl at pH 7.5 (Fig 4C) or diluted
into buffers containing 150 mMNaCl at pH values ranging from 6.5 to 8.5 (Fig 4D).
The CD spectra of MBP-linker-MPR-TM in buffers containing different ionic strength (Fig
4C) and pH (Fig 4D) all showed negative bands at 208 and 222 nm of almost the same molar
ellipticity. Our results indicate that the fusion protein MBP-linker-MPR-TM is stable under all
tested conditions. Therefore, crystallization screens of MBP-linker-MPR-TM could potentially
be carried out at a large range of ionic strength and pH, at which the protein will not be
denatured.
MBP-linker-MPR-TM is stable at high protein concentration
Crystallization screens often start with a protein concentration at 10 mg/mL, although the opti-
mal concentration for each protein should be experimentally determined as it depends on many
factors such as molecular weight and the stability of the protein at high concentration. Here, we
used SEC and DLS to test the stability of MBP-linker-MPR-TM at high protein concentration.
The protein was concentrated to 10 mg/mL by a 100-kDa cut-off concentrator to avoid concen-
tration of the detergent βDDM, whose micelle molecular weight is about 70 kDa [27]. The con-
centrated sample was stored at 4°C and analyzed by SEC and DLS at day 1, 3 and 7.
The size exclusion chromatogram (Fig 5A) revealed a main peak eluting at about 10 mL and
a very small minor peak eluting at 14.5 mL from day 1 to day 7. The main peak was expected to
contain oligomeric MBP-linker-MPR-TM/detergent complex while the small minor peak at
14.5 mL might represent the MBP protein. The small minor peak increased slightly from day
1 to day 7, which represented 0.4%, 0.7% and 1.5% of the total area respectively (insert in Fig
5A), but was still very small compared with the main peak after one week storage at 4°C.
The DLS measurements (Fig 5B, 5C and 5D and S4 Table) revealed a narrow peak at 7.1 to
7.6 nm with the percent polydispersity below 12% from day 1 to day 7, which indicates that the
protein sample is in a monodisperse condition for seven days at 4°C (Fig 5B, 5C and 5D and S4
Table). Although a small aggregation peak at 90.2 nm was detected on day 7, the aggregation
peak represented only 0.1% of the total amount (mass) of the protein because the increase in
scattered intensity is proportional to r6 (r is the particle radius) [57]. In conclusion, at a concen-
tration of 10 mg/mL, MBP-linker-MPR-TM was homogeneous and monodisperse for 7 days,
and therefore crystallization screens could be performed at this concentration.
MBP-linker-MPR-TM is recognized by the broadly neutralizing mAbs
2F5 and 4E10
An important feature of gp41 is that it contains the epitopes for broadly neutralizing antibodies
2F5 and 4E10, which makes gp41 an attractive target for vaccine design. However, the epitopes
for 2F5 and 4E10 cannot bind the antibodies in the pre-fusion and post-fusion conformations
of gp41 [22, 23]. HIV-1 gp41 mediates the membrane fusion between target cell and virus
through its own conformational change: native trimer prior to the interaction between gp120
and CD4, pre-hairpin intermediate and post-fusion trimer of hairpins (or a six-helix bundle)
[21]. It was reported by Frey et al that gp41 in its prefusion conformation could not interact
300 mMNaCl. (D) Effect of pH on the secondary structure of MBP-linker-MPR-TM. CD spectra were
recorded in 150 mMNaCl, 0.02% βDDM at pH 6.5 to 8.5.
doi:10.1371/journal.pone.0136507.g004
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with 2F5 or 4E10: gp41 in its post-fusion conformation binds 2F5 very weakly (KD 1.4 μM),
while gp41 in its pre-hairpin intermediate state binds 2F5 and 4E10 very strongly (KD< 10 nM)
[58]. Therefore, it is of great interest to measure the binding affinities of MBP-linker-MPR-TM
to 2F5 and 4E10 by surface plasmon resonance (SPR), from which the conformational informa-
tion of MPR-TM could be estimated.
SPR measurements showed that mAbs 2F5 and 4E10 bound strongly to MBP-linker-
MPR-TM with a KD of 0.5 nM for the 2F5 Ab and a KD of 0.4 nM for the 4E10 Ab (Fig 6 and
Table 1). This result suggests that MBP-linker-MPR-TMmay be in the pre-hairpin intermedi-
ate conformation, at which stage the epitopes for 2F5 and 4E10 are exposed and are available
for antibody binding. The weak unspecific binding of 2F5 and 4E10 to the negative control
MBP (fractions A2 from SEC purification, Fig 1C) may be due to the existence of high concen-
tration of maltose (10% maltose) in the antibody solution. However, the binding affinities of
MBP-linker-MPR-TM to mAbs 2F5 and 4E10 are much stronger than that of MBP. Therefore,
the strong binding of MBP-linker-MPR-TM to mAbs 2F5 and 4E10 is due to the presence of
MPR-TM instead of MBP.
Fig 5. Stability test of 10 mg/mLMBP-linker-MPR-TM.MBP-linker-MPR-TM (10 mg/mL) was stored at 4°C and measured by SEC and DLS on day 1, 3
and 7. (A) Stability test of 10 mg/mL MBP-linker-MPR-TM by SEC. Insert: magnification of the degradation peak, which indicated slight increase of the MBP-
linker-MPR-TM degradation from day 1 to day 7. (B-D) Stability test of 10 mg/mL MBP-linker-MPR-TM by DLS. The protein sample was homogeneous and
monodisperse for 7 days at 4°C; only a little protein aggregation was detected on day 7.
doi:10.1371/journal.pone.0136507.g005
Crystallizability of HIV gp41-MBP Fusion Proteins
PLOS ONE | DOI:10.1371/journal.pone.0136507 August 21, 2015 14 / 22
Alternation of the linker of MBP-linker-MPR-TM to three alanine residues
Extensive crystallization trials with screens of thousands of conditions using both vapor diffu-
sion method and liquid cubic phase did not yield crystals of MBP-linker-MPR-TM with dif-
fraction quality. Similar problems were reported by Center et al., who described that crystals
could not be obtained when the ectodomain of gp21 from human T cell leukemia virus type I
upon its fusion to the C-terminus of MBP via a flexible linker containing 25 residues until the
linker was changed to three alanine residues [59]. We applied their strategy to our study.
Therefore, the 42-residue-long linker containing a TEV protease recognition site was replaced
by a short, three-alanine linker (Fig 7). In addition, three charged residues at the C-terminus of
MBP (Glu-370, Lys-373 and Asp-374) were replaced by alanine residues to avoid potential
electrostatic repulsion between MBP monomers in the event that MPR-TM forms a trimer
[59]. The new fusion protein was dubbed MBP-AAA-MPR-TM.
We employed the purification procedure that was devised for MBP-linker-MPR-TM to
purify MBP-AAA-MPR-TM. Ni-affinity chromatography of MBP-AAA-MPR-TM (Fig 8A)
resulted in a single band at the expected apparent MW (49 kDa, Fig 8B), in contrast to prepara-
tions of the longer-linker fusion protein, which contained prominent contaminating degrada-
tion products (Fig 1A and 1B). The purity of the affinity chromatography eluate was further
demonstrated by a subsequent SEC, which exhibited a single peak (Fig 8A). The purity of
MBP-AAA-MPR-TM was almost 100%, estimated by the densitometry (S3B Fig). About
60 mg of pure MBP-AAA-MPR-TM protein was obtained from 1 liter of bacterial culture.
Fig 6. Surface plasmon resonance analysis of MBP-linker-MPR-TM. The mAbs 2F5 and 4E10 were
immobilized onto the surface of a gold chip (Plexera) and the purified MBP-linker-MPR-TM protein was the
analyte. MBP (fractions A2 from SEC purification, Fig 1C) was used as a negative control.
doi:10.1371/journal.pone.0136507.g006
Table 1. Binding rate constants of MBP-linker-MPR-TM derived from SPR analysisa.
Immobilized ligand Flowing analyte ka, M-1 s-1 (104) kd, s-1 (10−5) KD, nM
2F5 MBP-linker-MPR-TM 7.0 ± 1.2 3.5 ± 1.2 0.5 ± 0.2
4E10 MBP-linker-MPR-TM 4.8 ± 0.1 1.8 ± 0.5 0.4 ± 0.1
aResults are the average of four independent measurements and are listed as mean ± SD.
doi:10.1371/journal.pone.0136507.t001
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CD, DLS and SPRmeasurements of MBP-AAA-MPR-TM
CD spectroscopy measurements showed that the CD spectrum of MBP-AAA-MPR-TM was
very similar to that of MBP-linker-MPR-TM (Fig 9A). Analysis of the secondary structure con-
tent of MBP-AAA-MPR-TM by CDPro indicated 38.8 ± 2.3% α-helix, 13.9 ± 2.6% β-sheet and
47.4 ± 2.6% random coil, which is in good agreement with the secondary structure content of
MBP-linker-MPR-TM (39.3 ± 2.3% α-helix, 13.5 ± 1.8% β-sheet and 47.3 ± 1.5% random coil).
These results indicate that changing of the linker to three alanine residues did not affect the
secondary structure of the recombinant protein.
DLS analysis displayed one monomeric peak at 7.4 ± 0.4 nm, which corresponded to a protein/
detergent complex of 360 kDa (Fig 9B and S5 Table). The size estimation of MBP-AAA-MPR-TM
is slightly smaller than that of MBP-linker-MPR-TM (7.7 ± 0.5 nm and ~400 kDa, Fig 3 and S2
Table), which reflects the slightly smaller mass of MBP-AAA-MPR-TM.
As the longer linker could provide more flexibility of theMPR region for binding the broadly
neutralizing antibodies, we conducted SPRmeasurements to determine if theMBP-AAA-MPR-TM
protein still binds the antibodies with high affinity. The SPR result shown in Table 2 indicated that
both 2F5 and 4E10 bind toMBP-AAA-MPR-TMwith nanomolar to subnanomolar affinities: KD
values of 1.0 nM and 0.5 nMwere determined for 2F5 and 4E10, respectively (Fig 9C and Table 2).
It is therefore concluded that MBP-AAA-MPR-TM protein binds 2F5 and 4E10 antibodies with
Fig 7. Schematic representation of the sequence of MBP-linker-MPR-TM (A) and MBP-AAA-MPR-TM
(B). Amino acid changes in the C-terminus of MBP are underlined. Green: TEV protease recognition site
(residues 414–420).
doi:10.1371/journal.pone.0136507.g007
Fig 8. Purification of MBP-AAA-MPR-TM. (A) SEC of the Ni-affinity elution of MBP-AAA-MPR-TM. (B)
Silver stained SDS-PAGE analysis of purification fractions.
doi:10.1371/journal.pone.0136507.g008
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nanomolar to sub-nanomolar affinities, which suggests it may be suitable as a component in a
future vaccine against HIV-1.
Conclusion
In summary, we describe here the expression and purification of two recombinant protein vari-
ants consisting of a fusion between MBP and MPR-TM of HIV-1 gp41. In one of these variants,
Fig 9. CD, DLS and SPRmeasurements of MBP-AAA-MPR-TM. (A) Comparison of CD spectra of MBP-
linker-MPR-TM and MBP-AAA-MPR-TM. (B) DLSmeasurement of 1 mg/ml MBP-AAA-MPR-TM showed one
monodisperse peak at 7.4 ± 0.8 nm. (C) SPR analysis. The mAbs 2F5 and 4E10 were immobilized onto the
surface of a gold chip (Plexera) and the purified MBP-AAA-MPR-TM protein was the analyte.
doi:10.1371/journal.pone.0136507.g009
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MPR-TM was fused to the C-terminus of MBP via a 42-aa-long linker containing a TEV prote-
ase recognition site. In the second variant, the long linker was replaced by a short and struc-
tured peptide consisting of three alanine residues. Both proteins were purified to homogeneity
and were shown to be stable in solution under various conditions and to remain monodisperse
over time. Both proteins were able to strongly interact in solution with the broadly neutralizing
mAbs 2F5 and 4E10 with nanomolar to sub-nanomolar affinities, in good agreement with our
previously published results concerning MPR-TM [27]. The longer linker variant MBP-linker-
MPR-TM was not amenable to crystallization under exhaustive screening. Crystallization
experiments of MBP-AAA-MPR-TM are currently underway.
Supporting Information
S1 Fig. Amino acid sequence of MBP-linker-MPR-TM. The color scheme is as follows: blue,
8His-MBP (residues 1–378); black and green: 42 aa-long linker (residues 379–420) containing
a TEV protease recognition site; green: TEV protease recognition site (residues 414–420); red:
MPR-TM (residues 421–479).
(EPS)
S2 Fig. Anti-His Western blot analysis of the detergent solublization of MBP-linker-
MPR-TM. (A) Cell lysate fractions. (B) Comparison of the extraction efficiency of different
detergents. (C) Determination of the time needed for efficient detergent extraction.
(TIF)
S3 Fig. Purity estimation of MBP-linker-MPR-TM and MBP-AAA-MPR-TM. SDS-PAGE
was overloaded with 50 μg of MBP-linker-MPR-TM and MBP-AAA-MPR-TM proteins for a
more sensitive detection of protein impurities.
(TIF)
S4 Fig. Clear native PAGE analysis of MBP-linker-MPR-TM and MBP-AAA-MPR-TM.
Native gels were prepared as described under Materials and Methods. Considering the very
low polydispersity of our preparations seen by both SEC and DLS, it was expected that subject-
ing the protein to electrophoresis under non-denaturing conditions would result in a single
band corresponding to the oligomeric protein. However, when preparations of the fusion pro-
tein were subjected to clear native PAGE (S4 Fig) as well as other nondenaturing PAGE proto-
cols (data not shown) [41, 42] we observed a ladder pattern indicating multiple oligomeric
forms. In contrast, the cleaved MBP fusion partner resolves as a monomer (S4 Fig). Pre-stained
protein standards resolve according to their molecular masses, however the MBP-linker-
MPR-TM protein migrate according to a more complex (largely empiric) function of its charge
and mass. In addition, the electrophoresis was conducted in the absence of detergents (in either
the gel or the running buffer), and the β-DDM present in the protein samples was expected to
be progressively diluted during the run. Consequently, assessing the molecular mass of the pro-
tein bands and determining their oligomeric configuration is speculative and is probably a
Table 2. Binding rate constants of MBP-AAA-MPR-TM derived from SPR analysisa.
Immobilized ligand Flowing analyte ka, M-1 s-1 (104) kd, s-1 (10−5) KD, nM
2F5 MBP-AAA-MPR-TM 2.1 ± 0.3 2.1 ± 0.8 1.0 ± 0.5
4E10 MBP-AAA-MPR-TM 0.73 ± 0.13 0.37 ± 0.18 0.5 ± 0.1
aResults are the average of four independent measurements and are listed as mean ± SD.
doi:10.1371/journal.pone.0136507.t002
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consequence of the PAGE. Two plausible interpretations are offered in S3 Table.
(TIF)
S5 Fig. Generation by cleavage and purification of MPR-TM. SDS-PAGE analysis of purifi-
cation fractions stained by coomassie blue. Lane 1: proteins standards; lane 2: TEV cleavage
products; lane 3: negative control (no TEV protease was added); lane 4: Ni-NTA flowthrough
containing MPR-TM; lane 5: Ni-NTA elution containing MBP and TEV protease.
(TIF)
S1 Table. Primer sequences.
(DOCX)
S2 Table. DLS measurement of purified MBP-linker-MPR-TM.
(DOCX)
S3 Table. MPR-TM fusion proteins resolve as regularly spaced bands by clear native PAGE.
(DOCX)
S4 Table. DLS measurements of MBP-linker-MPR-TM (10 mg/mL) subjected to prolonged
incubation at 4°C.
(DOCX)
S5 Table. DLS measurement of purified MBP-AAA-MPR-TM.
(DOCX)
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